#ESMO22: Trailing Roche’s Tecentriq, immune checkpoint therapies meet untreated liver cancer with mixed results
PARIS — In 2020, Roche’s Tecentriq, a PD-L1 inhibitor, got an FDA nod in combination with Avastin for untreated advanced liver cancer, becoming the first immune checkpoint therapy to make it to the first line for these tumors. That approval, deemed a “landmark,” came on the back of a Phase III trial that showed the Tecentriq combo prolonged survival longer than Nexavar — the Bayer drug that had stood unbeaten as the standard of care in first line liver cancer since 2007.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.